% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Apr 24, 2013 6:29 PM Flag

    Kot/J/Nesh et al - Celldex and Genentech paper

    Published April 8, 2013
    The Rockefeller University Press, doi: 10.1084/jem.20121251
    © 2013 Cohn et al.
    Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation
    Lillian Cohn1, Bithi Chatterjee1, Filipp Esselborn1, Anna Smed-Sörensen1,2, Norihiro Nakamura1, Cécile Chalouni1, Byoung-Chul Lee1, Richard Vandlen1, Tibor Keler3, Peter Lauer4, Dirk Brockstedt4, Ira Mellman1, and Lélia Delamarre1
    + Author Affiliations
    1Genentech, South San Francisco, CA 94080
    2Karolinska Institutet, 171 77 Solna, Sweden
    3Celldex Therapeutics Inc., Phillipsburg, NJ 08865
    4Aduro BioTech, Inc., Berkeley, CA 94710
    Human BDCA3+ dendritic cells (DCs), the proposed equivalent to mouse CD8α+ DCs, are widely thought to cross present antigens on MHC class I (MHCI) molecules more efficiently than other DC populations. If true, it is unclear whether this reflects specialization for cross presentation or a generally enhanced ability to present antigens on MHCI. We compared presentation by BDCA3+ DCs with BDCA1+ DCs using a quantitative approach whereby antigens were targeted to distinct intracellular compartments by receptor-mediated internalization. As expected, BDCA3+ DCs were superior at cross presentation of antigens delivered to late endosomes and lysosomes by uptake of anti-DEC205 antibody conjugated to antigen. This difference may reflect a greater efficiency of antigen escape from BDCA3+ DC lysosomes. In contrast, if antigens were delivered to early endosomes through CD40 or CD11c, BDCA1+ DCs were as efficient at cross presentation as BDCA3+ DCs. Because BDCA3+ DCs and BDCA1+ DCs were also equivalent at presenting peptides and endogenously synthesized antigens, BDCA3+ DCs are not likely to possess mechanisms for cross presentation that are specific to this subset. Thus, multiple DC populations may be comparably effective at presenting exogenous antige

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • United States Patent Application 20130101593
      Kind Code A1
      KELER; Tibor ; et al. April 25, 2013


      Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

      Inventors: KELER; Tibor; (Ottsville, PA) ; HE; Lizhen; (Allentown, PA) ; RAMAKRISHNA; Venky; (Riegelsville, PA) ; VITALE; Laura A.; (Doylestown, PA)
      Applicant: Name City State Country

      Celldex Therapeutics Inc.;

      Sentiment: Strong Buy

    • Celldex's employees are prolific authors!

11.88+1.31(+12.39%)Oct 2 4:00 PMEDT